  |
|
 |
|
Case Report
| ||||||
| Quetiapine associated dyslipidemia and hyperglycemia in a pediatric overweight patient | ||||||
| Elizabeth Carreño1, Vivekananda Dasari1, Aditya Badheka1, Shanti Yogananda1, Swati Dave-Sharma1 | ||||||
|
1Department of Pediatrics, Lincoln Medical & Mental Health Center, Bronx, NY, United States.
| ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] 
|
| How to cite this article: |
| Carreño E, Dasari V, Badheka A, Yogananda S, Dave-Sharma S. Quetiapine associated dyslipidemia and hyperglycemia in a pediatric overweight patient. International Journal of Case Reports and Images 2013;4(2):120–122. |
|
Abstract
|
|
Introduction:
Atypical antipsychotics like quetiapine, can cause undesirable alterations in lipid profile and hyperglycemia. They are associated with metabolic and cardiovascular-related adverse events in pediatric population, especially when multiple antipsychotics or classes of psychotropic medications are co-prescribed.
Case Report: A 15-year-old, overweight, Hispanic male child was referred to the endocrinology clinic by his primary care provider due to high serum cholesterol, triglyceride and glucose levels. Past history was significant for autism, anxiety with depression and attention deficit disorder for which he was getting psychiatric care and was receiving quetiapine 50 mg daily for more than two years. Physical examination was significant for increased adiposity and overweight. Fasting laboratory studies showed elevated cholesterol and triglycerides. In addition to lifestyle modification including diet and exercise, quetiapine was discontinued and replaced by aripiprazole. Repeat testing after four months showed normalized cholesterol and triglyceride levels. Conclusion: The use of atypical antipsychotics prescribed to children and adolescents with neuropsychiatric disorders has been associated with various adverse effects, including significant weight gain. These adverse effects are of particular concern in children and adolescents due to the immediate and long term health risks associated with weight gain, including obesity, diabetes mellitus and hyperlipidemia. | |
|
Keywords:
Quetiapine, Dyslipidemia, Hyperglycemia, Overweight, Pediatric
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions
Elizabeth Carreño – Substantial contributions to conception and design, Acquisition of data, Drafting the article, revising it critically for important intellectual content, Final approval of the version to be published Aditya Badheka – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Vivekananda Dasari – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Shanti Yogananda – Substantial contributions to conception and design, Acquisition of data, Drafting the article, revising it critically for important intellectual content, Final approval of the version to be published Swati Dave-Sharma – Substantial contributions to conception and design, Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© Elizabeth Carreño et al. 2013; This article is distributed the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any means provided the original authors and original publisher are properly credited. (Please see Copyright Policy for more information.) |
|
|